TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7033789

Group type: EXPERIMENTAL
Intervention: D-penicillamine (250 mg four times a day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (identical to D-penicillamine)
Number of subjects: 52
Study: 30703070

Group type: EXPERIMENTAL
Intervention: Visual plus verbal feedback
Number of subjects: 38

Group type: COMPARATOR
Intervention: Verbal feedback only
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: High neuroticism
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Conscientiousness and agreeableness
Number of subjects: 38
Study: 28682725

Group type: EXPERIMENTAL
Intervention: Alginate silver dressing (Ag group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Normal saline solution gauze (NSS group)
Number of subjects: 39
Study: 26404298

Group type: EXPERIMENTAL
Intervention: RF generated M-VLTR shock
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: RF generated B-VLTR shock
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: RF generated M-VLTR or B-VLTR shock
Number of subjects: 30
Study: 23566765

Group type: EXPERIMENTAL
Intervention: G1 - as-machined
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: G2 - glazed
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: G3 - diamond bur finishing
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: G4 - G3 + OptraFine(®) polishing kit
Number of subjects: 32
Study: 21440461

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (IMN)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 50
Study: 19606450

Group type: EXPERIMENTAL
Intervention: Randomization method using a spreadsheet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomization database
Number of subjects: 0
Study: 18083374

Group type: EXPERIMENTAL
Intervention: Interferon (IFN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wide margins, elective lymph node dissection, sentinel lymph node (SLN) biopsy, prophylactic isolated limb perfusion (ILP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic adjuvant therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapeutic drugs, immunostimulants, and various vaccines
Number of subjects: 0
Study: 15122604

Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open fundoplication
Number of subjects: 60
Study: 11934652

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE; 0.625 mg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 9832936

Group type: EXPERIMENTAL
Intervention: 50 mg caffeine
Number of subjects: 21

Group type: COMPARATOR
Intervention: 0 mg nicotine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.25 mg nicotine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.5 mg nicotine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 1.0 mg nicotine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 1 mg nicotine
Number of subjects: 21
Study: 7852227

Group type: EXPERIMENTAL
Intervention: Idiopathic epilepsy patients on day 1 and day 4 of seizures
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Idiopathic epilepsy patients on day 7 of seizures
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Severe epilepsy and status epilepticus
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mild and moderate epilepsy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal healthy controls
Number of subjects: 50
Study: 2838426

Group type: EXPERIMENTAL
Intervention: Oral iodized oil (2 ml)
Number of subjects: 5999

Group type: EXPERIMENTAL
Intervention: Intramuscular iodized oil (2 ml)
Number of subjects: 5999

Group type: COMPARATOR
Intervention: Potassium iodide (0.5 g, 1.0 g, and 2.0 g)
Number of subjects: 5999

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5999
Study: 31055677

Group type: EXPERIMENTAL
Intervention: Visual attention training (twice a week for 45 min sessions over 3 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 30
Study: 28954842

Group type: EXPERIMENTAL
Intervention: Whole-Grain Wheat (WGW)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Whole-Grain Rye (WGR)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Refined Wheat (RW)
Number of subjects: 70
Study: 26493038

Group type: EXPERIMENTAL
Intervention: 5‐monthly fixed dosing of Ozurdex
Number of subjects: 100

Group type: COMPARATOR
Intervention: OCT‐guided PRN regimen of Ozurdex
Number of subjects: 100
Study: 21691780

Group type: EXPERIMENTAL
Intervention: Closed reduction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Open reduction
Number of subjects: 40
Study: 21577082

Group type: EXPERIMENTAL
Intervention: Perceptual training group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 19566689

Group type: EXPERIMENTAL
Intervention: Voice simulation experience
Number of subjects: 28
Study: 16491463

Group type: EXPERIMENTAL
Intervention: Single phosphate enema
Number of subjects: 294

Group type: COMPARATOR
Intervention: Oral polyethylene glycol (PEG) solution (3 litres)
Number of subjects: 294
Study: 15243275

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (n = 87)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Stretching control group (n = 86)
Number of subjects: 173
Study: 11395986

Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation (FeSO4) for 18 weeks
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo for 18 weeks
Number of subjects: 73
Study: 9257425

Group type: EXPERIMENTAL
Intervention: Sargramostim (300 micrograms; 193 mg/m2)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Filgrastim (481 mg; 7 mg/kg)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Sargramostim and Filgrastim
Number of subjects: 137
Study: 8400081

Group type: EXPERIMENTAL
Intervention: Complement-activating membrane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noncomplement-activating membrane
Number of subjects: 0
Study: 3037835

Group type: EXPERIMENTAL
Intervention: High-dose ketoconazole (400 mg every 8 h)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High-dose ketoconazole (400 mg every 8 h) + Dexamethasone (0.5 mg twice daily)
Number of subjects: 7
Study: 30791879

Group type: EXPERIMENTAL
Intervention: Web-based educational tool providing information on non-specific chronic low back pain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Video explaining clinical practice guidelines on low back pain
Number of subjects: 0
Study: 27975209

Group type: EXPERIMENTAL
Intervention: Exendin (9-39) (Ex-9)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 24435222

Group type: EXPERIMENTAL
Intervention: Mobile-bearing prosthesis
Number of subjects: 94

Group type: COMPARATOR
Intervention: Fixed-bearing prosthesis
Number of subjects: 94
Study: 22986111

Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 50

Group type: COMPARATOR
Intervention: Trabeculectomy with adjunctive mitomycin C
Number of subjects: 50
Study: 21432224

Group type: EXPERIMENTAL
Intervention: On-the-job training (OJT) with guidance by an orthopedist and an exercise instructor, and stretching exercises for 6 min every day.
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 88
Study: 19025306

Group type: EXPERIMENTAL
Intervention: Somatostatin (SOM, 250 mg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Octreotide (OCT, 50 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 45
Study: 20087643

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246

Group type: COMPARATOR
Intervention: Transdermal nicotine and behavioral counseling
Number of subjects: 246
Study: 16366759

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LAAM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 12091996

Group type: EXPERIMENTAL
Intervention: Filgrastim treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular treatment (without filgrastim)
Number of subjects: 0
Study: 9494305

Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene (DPP) 120 mg to 240 mg daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Controlled-release morphine 20 mg daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene (DPP)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Controlled-release morphine
Number of subjects: 32
Study: 8036118

Group type: EXPERIMENTAL
Intervention: Bilateral stimulus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipsilateral stimulus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two stimuli with different intensities on the same tongue side
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suprathreshold stimuli
Number of subjects: 0
Study: 3141290

Group type: EXPERIMENTAL
Intervention: bacampillin 800 mg b.i.d. for ten days
Number of subjects: 301

Group type: COMPARATOR
Intervention: amoxicillin 500 mg t.i.d. for ten days
Number of subjects: 301

Group type: COMPARATOR
Intervention: amoxicillin 500 mg t.i.d.
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: bacampillin 800 mg b.i.d.
Number of subjects: 301
Study: 30106834

Group type: EXPERIMENTAL
Intervention: Cytology
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: FISH
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Molecular Profiling (MP)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Combination of Cytology, FISH, and MP
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: MP
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Combination of FISH and MP
Number of subjects: 101
Study: 30128092

Group type: EXPERIMENTAL
Intervention: Persian Medicine Protocol (intranasal lavender oil, Liquorice Marjoram Tea)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Classical treatment (systemic and intranasal cortisone)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Persian Medicine Protocol
Number of subjects: 42
Study: 27769828

Group type: EXPERIMENTAL
Intervention: Electronic vapour product (EVP; 2.0% nicotine)
Number of subjects: 0
Study: 24268300

Group type: EXPERIMENTAL
Intervention: Immediate Education (IE)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Delayed Education (DE)
Number of subjects: 134
Study: 22006207

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (Swisse Women's 50+ Ultivite ®)
Number of subjects: 56
Study: 19766948

Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy (MST)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Group weight‐loss intervention (Control)
Number of subjects: 48
Study: 17261560

Group type: EXPERIMENTAL
Intervention: Custom fit semirigid insoles
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Physiotherapy (10 treatments: deep‐friction, pulsed ultrasound, ice, sensory motor training)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 31
Study: 15536619

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 1190

Group type: EXPERIMENTAL
Intervention: Recent smokers
Number of subjects: 1190

Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 1190

Group type: EXPERIMENTAL
Intervention: Never-smokers
Number of subjects: 1190

Group type: EXPERIMENTAL
Intervention: Patients who quit smoking within 12 months before randomization
Number of subjects: 1190

Group type: EXPERIMENTAL
Intervention: Patients who were current smokers at randomization
Number of subjects: 1190

Group type: EXPERIMENTAL
Intervention: Former smokers and recent quitters who continued to abstain from smoking during follow-up
Number of subjects: 1190
Study: 11260582

Group type: EXPERIMENTAL
Intervention: Child behavior informational intervention for mothers
Number of subjects: 49
Study: 9543905

Group type: EXPERIMENTAL
Intervention: Patient education intervention (one-on-one education session by a nephrology nurse using a teaching booklet, Osteodystrophy Tool, and medication diary)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Patient education intervention
Number of subjects: 29
Study: 7509380

Group type: COMPARATOR
Intervention: Taxol (paclitaxel) 250 mg/m2 without G-CSF
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Taxol (paclitaxel) 300 mg/m2 with G-CSF
Number of subjects: 35

Group type: COMPARATOR
Intervention: Taxol (paclitaxel) 250 mg/m2
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Taxol (paclitaxel)
Number of subjects: 35
Study: 3132962

Group type: EXPERIMENTAL
Intervention: Thrombolytic treatment with intracoronary streptokinase
Number of subjects: 533
Study: 30012789

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 34
Study: 26832888

Group type: EXPERIMENTAL
Intervention: Progesterone and Vitamin D
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 24684254

Group type: EXPERIMENTAL
Intervention: Robotic/endoscopic thyroidectomy (GUAB/GUA approaches)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Robotic/endoscopic thyroidectomy (GUA approach)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Conventional open thyroidectomy
Number of subjects: 147
Study: 23517257

Group type: COMPARATOR
Intervention: SCUBE‐1 levels at 2 hours (Group IV)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Total oxidative status (TOS) at 30 minutes and 2 hours
Number of subjects: 36

Group type: COMPARATOR
Intervention: Oxidative stress index (OSI) at 30 minutes and 2 hours
Number of subjects: 36

Group type: COMPARATOR
Intervention: SCUBE‐1 levels at 6 hours (Group VI)
Number of subjects: 36

Group type: COMPARATOR
Intervention: MDA, TAS, TOS, and OSI levels
Number of subjects: 36
Study: 20595563

Group type: EXPERIMENTAL
Intervention: Minimally invasive knee instruments
Number of subjects: 134

Group type: COMPARATOR
Intervention: Standard approach
Number of subjects: 134
Study: 18450124

Group type: EXPERIMENTAL
Intervention: Single dose of 2000 microg nebulized budesonide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Repeated doses of 4 x 500 microg nebulized budesonide
Number of subjects: 40
Study: 17162433

Group type: EXPERIMENTAL
Intervention: Standard heparin
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no anticoagulant)
Number of subjects: 33
Study: 12225269

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrolysed milk formulas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined dietary manipulation plus airborne allergen avoidance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exclusive breastfeeding for three months
Number of subjects: 0

Group type: COMPARATOR
Intervention: High intake of omega-3 fatty acids (regular fish consumption)
Number of subjects: 0
Study: 10426453

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 plus doxorubicin 50 mg/m2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m2 plus doxorubicin 60 mg/m2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel plus doxorubicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxorubicin plus cyclophosphamide
Number of subjects: 0
Study: 8848891

Group type: EXPERIMENTAL
Intervention: mivacurium (150 and 70 micrograms kg‐1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: mivacurium preceded by atracurium (350 and 75 micrograms kg‐1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: mivacurium preceded by vecuronium (70 and 15 micrograms kg‐1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: mivacurium (final dose 70 micrograms kg‐1)
Number of subjects: 45
Study: 2194509

Group type: EXPERIMENTAL
Intervention: 60% carbohydrate diet
Number of subjects: 11

Group type: COMPARATOR
Intervention: 40% carbohydrate diet
Number of subjects: 11
Study: 354329

Group type: EXPERIMENTAL
Intervention: Fluphenazine enanthate (high doses, 10-20 times higher than normal)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluphenazine enanthate (high doses)
Number of subjects: 12
Study: 28636188

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (continued on pressure lowering medication)
Number of subjects: 143
Study: 27236073

Group type: EXPERIMENTAL
Intervention: Mindful acceptance induction
Number of subjects: 79

Group type: COMPARATOR
Intervention: Thought wandering induction
Number of subjects: 79
Study: 24357798

Group type: EXPERIMENTAL
Intervention: Four-factor model including any two of the four intermediate-risk factors (tumour size ≥3 cm, DSI of the outer third of the cervix, LVSI, and adenocarcinoma or adenosquamous carcinoma histology)
Number of subjects: 2158

Group type: EXPERIMENTAL
Intervention: Development group
Number of subjects: 2158

Group type: COMPARATOR
Intervention: Validation group
Number of subjects: 2158

Group type: EXPERIMENTAL
Intervention: Four factors (histology, tumour size, DSI, LVSI)
Number of subjects: 2158
Study: 22101760

Group type: EXPERIMENTAL
Intervention: Tocilizumab (4 or 8 mg/kg intravenous infusions every 4 weeks for a total of 6 doses)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 4
Study: 20637042

Group type: EXPERIMENTAL
Intervention: Letter with a proposed date
Number of subjects: 3245

Group type: EXPERIMENTAL
Intervention: Telephone call
Number of subjects: 3245

Group type: EXPERIMENTAL
Intervention: Letter without a proposed date
Number of subjects: 3245
Study: 18676327

Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiation with gemcitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 16650792

Group type: EXPERIMENTAL
Intervention: Familial Mediterranean fever (FMF) patients
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Behçet's disease (BD) patients
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 98
Study: 12786629

Group type: EXPERIMENTAL
Intervention: Repifermin 1 microg/kg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Repifermin 5 microg/kg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Repifermin 10 microg/kg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Repifermin 25 microg/kg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Repifermin 50 microg/kg
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 10999807

Group type: EXPERIMENTAL
Intervention: Iodine supplementation during pregnancy and postpartum (150 microg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Iodine supplementation during pregnancy only (150 microg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: No iodine supplementation
Number of subjects: 66
Study: 9547125

Group type: EXPERIMENTAL
Intervention: Multidisciplinary packages of care for spouses of older people with psychiatric illness
Number of subjects: 0

Group type: COMPARATOR
Intervention: No extra help (Control)
Number of subjects: 0
Study: 8345382

Group type: EXPERIMENTAL
Intervention: Surfactant administration by pump
Number of subjects: 22

Group type: COMPARATOR
Intervention: Surfactant administration by hand-dosing method
Number of subjects: 22
Study: 3088085

Group type: EXPERIMENTAL
Intervention: Health education to improve asthma management at home
Number of subjects: 310

Group type: COMPARATOR
Intervention: Control group (no health education)
Number of subjects: 310
Study: 30509204

Group type: EXPERIMENTAL
Intervention: Geriatric Emergency Department Intervention (GEDI) model
Number of subjects: 44983
Study: 27567144

Group type: EXPERIMENTAL
Intervention: Early intervention (<12 h)
Number of subjects: 542

Group type: COMPARATOR
Intervention: Late intervention (>48 h)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Overall TSTE patients
Number of subjects: 542

Group type: COMPARATOR
Intervention: Overall non-TSTE patients
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Overall TSTE patients (2-year follow-up)
Number of subjects: 542

Group type: COMPARATOR
Intervention: Overall non-TSTE patients (2-year follow-up)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Early intervention (2-year follow-up)
Number of subjects: 542

Group type: COMPARATOR
Intervention: Late intervention (2-year follow-up)
Number of subjects: 542
Study: 24327590

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention (medication reconciliation and patient education)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 61
Study: 22264669

Group type: EXPERIMENTAL
Intervention: 10 rTMS sessions delivered at 1 Hz to the right dorsolateral prefrontal cortex (DLPRC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10 sham rTMS sessions to the same area
Number of subjects: 20
Study: 20662955

Group type: EXPERIMENTAL
Intervention: Intervention group (up to 11 home and telephone contacts over 16 weeks)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 272
Study: 18356697

Group type: EXPERIMENTAL
Intervention: Nicorandil therapy (15 mg/day; n = 26)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Usual care (n = 27)
Number of subjects: 53
Study: 15976964

Group type: EXPERIMENTAL
Intervention: INR self-management
Number of subjects: 2951

Group type: COMPARATOR
Intervention: Conventional INR management
Number of subjects: 2951
Study: 11588506

Group type: EXPERIMENTAL
Intervention: Exclusive breast feeding
Number of subjects: 272

Group type: COMPARATOR
Intervention: Breast milk plus other foods
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: HIV-infected infants
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Feeding mode
Number of subjects: 272
Study: 9735589

Group type: EXPERIMENTAL
Intervention: Random assignment to day-hospital or inpatient rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonrandom assignment (self-selected treatment)
Number of subjects: 0